Lipidome and Microbiome Profile of the Eye in Rosacea

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: University of California, Davis

No Placebo Group

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial studies how antibiotics change lipid molecules and the microbiome in people with rosacea. It aims to find new ways to treat rosacea by understanding these changes, potentially reducing the need for antibiotics.

Research Team

Mark Mannis, MD

Principal Investigator

UC Davis, Department of Ophthalmology

Raja Sivamani, MD, MS

Principal Investigator

UC Davis, Department of Dermatology

Eligibility Criteria

Inclusion Criteria

Aged 18 and older

Healthy subjects without an inflammatory facial rash or an inflammatory eye condition

Subjects diagnosed with ocular rosacea or cutaneous rosacea (papulopustular or erythematotelangiectatic) by either a board-certified dermatologist or ophthalmologist

Treatment Details

Interventions

• Doxycycline (Tetracycline Antibiotic)

Participant Groups

Group I: Ocular Rosacea Subjects Experimental Treatment 1 Intervention

Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.

Group II: Cutaneous Rosacea Subjects Experimental Treatment 1 Intervention

Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxycycline intervention.

Group III: Healthy Subjects Active Control 1 Intervention

Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.

Doxycycline is already approved in Canada, Japan for the following indications:

Approved in Canada as Doxycycline for:

• Acne
• Bacterial infections
• Chlamydia
• Gonorrhea
• Lyme disease
• Malaria
• Pneumonia
• Rosacea
• Urinary tract infections

Approved in Japan as Doxycycline for:

• Acne
• Bacterial infections
• Chlamydia
• Gonorrhea
• Lyme disease
• Malaria
• Pneumonia
• Rosacea
• Urinary tract infections

Who Is Running the Clinical Trial?

University of California, Davis

Lead Sponsor

Trials

958

Recruited

4,816,000+